Nanotechnology Now

Our NanoNews Digest Sponsors



Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > BioAlliance Pharma Complements Its Portfolio with a European License for Ondansetron RapidFilm™

Abstract:
A new innovative product near registration filing in cancer supportive care

BioAlliance Pharma Complements Its Portfolio with a European License for Ondansetron RapidFilm™

PARIS, France | Posted on August 5th, 2008

BioAlliance Pharma SA. (Paris:BIO), the specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV, and APR Applied Pharma Research SA., together with its joint venture partner Labtec GmbH, today announced that they have entered into an exclusive licensing agreement under which BioAlliance has acquired the commercialization rights in Europe to the thin film formulation of ondansetron from APR/Labtec, leader in oral thin film technology named RapidFilmTM. Ondansetron thin film formulation is a new oral formulation for the prevention of chemotherapy-induced nausea and vomiting, prevention of nausea and vomiting associated with radiotherapy, and post-operative nausea and vomiting.

Based on the results of a recently completed bio-equivalency study, BioAlliance will be preparing registration in Europe. The exclusive license to BioAlliance may total up to € 6.0 million with € 1 million at signature and € 1,25 million at approval and sales milestones up to € 3,75 million; in addition royalties on net sales of the product will also be paid.

Anti-emetic therapies constitute one of the largest segments of the supportive care market in Europe, with annual sales of over € 400 million in 2007 in the 5 major EU markets (IMS Midas 2007). Ondansetron was the prescription leader in the category in 2007, with about 800 000 prescriptions (as extrapolated from IMS Midas Medical Data 2007).

APR/Labtec´s proprietary RapidFilmTM technology is a novel, non-mucoadhesive, fast dissolving oral dosage form. It features a thin film based on a water-soluble polymer. The film disintegrates rapidly within seconds in contact with water or saliva, releases the drug in the mouth and promotes gastrointestinal absorption. The RapidFilmTM dosage form was especially designed for high patient compliance. The application is easy. The patient does not have any swallowing difficulty. The fact that no water intake after administration is needed is very well accepted by patients with nausea.

Dominique Costantini, CEO of BioAlliance said, "We are delighted to collaborate with APR/Labtec and expand our pipeline of supportive care products. With two unique, yet complementary delivery systems of ondansetron in our portfolio, ondansetron oral spray from NovaDel and the oral thin film, we are able to offer patients a better opportunity to find a product that meets their individual needs."

Paolo Galfetti, CEO of APR, stated, "BioAlliance is uniquely positioned to market and sell our ondansetron thin film product and we are very excited about the collaboration. Following approval, ondansetron is expected to be the first prescription drugs to come to market utilizing thin film drug delivery technology".

####

About BioAlliance Pharma SA.
BioAlliance Pharma SA is a specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV. The company develops and commercializes innovative products which address resistance issues. The company has launched its first portfolio product (Loramyc®) in France and already received European Marketing Authorizations in UK, Germany, Belgium, Denmark and Luxemburg. The compound has completed the pivotal Phase III clinical development in oropharyngeal candidiasis in the USA. In addition, two other innovative products are currently in Phase III clinical trials: acyclovir Lauriad® in oral herpes (based on the same Lauriad® muco-adhesive technology as Loramyc®, which enables targeted release at the disease site) and doxorubicin Transdrug® in primary liver cancer (based on the Transdrug® nanoparticle technology, designed specifically for intracellular targeting of resistant cells - this trial is currently suspended on the advice from the Data Safety Monitoring Board and Steering Committee, while waiting for additional clinical functional data). The company is also developing a new therapeutic entities program focused on the oncology and infectious disease markets.

In 2007, the company has established strategic alliances for commercializing Loramyc® in Europe (with JV SpeBio) and in the USA with Par Pharmaceutical. In March 2008, BioAlliance Pharma signed a partnership agreement with Handok Pharmaceuticals for commercializing Loramyc® in Korea, Taiwan, Singapore and Malaysia and with Novamed Pharmaceuticals in June 2008 for commercialization of Loramyc™ in China. In May 2008, the company expanded its product portfolio via acquisition of the European commercial rights to ondansetron Oral Spray (OS) from NovaDel Pharma Inc. (Amex: NVD).

For more information, visit BioAlliance Pharma's website at www.bioalliancepharma.com.

About APR Applied Pharma Research s.a.

APR is a private Research & Development company headquartered in Switzerland. Core business is the development of its own selected drug candidates (developed using APR proprietary technologies) as well as on the development under contract of third party pharmaceutical products and medical devices. Leveraging on its own technology platforms, R&D know-how, marketing and regulatory expertise, APR is committed to create new sustainable value on its own as well as on third party products and projects.

The APR products and technologies are licensed to third parties for distribution and marketing. R&D activities are carried out directly or under contract.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the reference document approved by the AMF on April 11 2008 under the number R. 08-021, which is available on the AMF website (www.amf-france.org) or on BioAlliance Pharma S.A.'s website (www.bioalliancepharma.com).

For more information, please click here

Contacts:
BioAlliance Pharma SA
Dominique Costantini
+33 1 45 58 76 01
President and CEO

or
Nicolas Fellmann
+33 1 45 58 71 00
CFO

or
APR
APR Applied Pharma Research s.a.
Paolo Galfetti
+41 91 69 57 020
CEO
Via Corti 5, CH-6828 Balerna, Switzerland
www.apr.ch
or
ALIZE RP
Caroline Carmagnol
+33 6 64 18 99 59

Copyright © Business Wire 2008

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

New synthesis method may shape future of nanostructures, clean energy: Findings advance efficient solar spliting of water into hydrogen fuel September 2nd, 2014

Accounting for Biological Aggregation in Heating and Imaging of Magnetic Nanoparticles September 2nd, 2014

Engineers develop new sensor to detect tiny individual nanoparticles September 2nd, 2014

Future solar panels September 2nd, 2014

Nanomedicine

Accounting for Biological Aggregation in Heating and Imaging of Magnetic Nanoparticles September 2nd, 2014

Nano-forests to reveal secrets of cells September 2nd, 2014

Nanoscale assembly line August 29th, 2014

Copper shines as flexible conductor August 29th, 2014

Announcements

New synthesis method may shape future of nanostructures, clean energy: Findings advance efficient solar spliting of water into hydrogen fuel September 2nd, 2014

Accounting for Biological Aggregation in Heating and Imaging of Magnetic Nanoparticles September 2nd, 2014

Engineers develop new sensor to detect tiny individual nanoparticles September 2nd, 2014

Future solar panels September 2nd, 2014

Patents/IP/Tech Transfer/Licensing

New analytical technology reveals 'nanomechanical' surface traits August 29th, 2014

AQUANOVA receives Technology Leadership Award 2014 FROST & SULLIVAN honors NovaSOL® Technology again August 12th, 2014

Blacktrace Holdings Ltd. to in-license PerkinElmer Technology August 8th, 2014

Silicene Labs Announces the Launch of Patent-Pending, 2D Materials Composite Index™ : The Initial 2D Materials Composite Index™ for Q2 2014 Is: 857.3; Founders Include World-Renowned Physicist and Seasoned Business and IP Professionals July 24th, 2014

Alliances/Partnerships/Distributorships

Leading European communications companies and research organizations have launched an EU project developing the future 5th Generation cellular mobile networks August 28th, 2014

JPK expands availability of instrumentation in the USA – appointing new distributors – launched a new web site to support the US market - AFM now available to US users August 26th, 2014

Sunblock poses potential hazard to sea life August 20th, 2014

SouthWest NanoTechnologies Appoints Matteson-Ridolfi for U.S. Distribution of its SMW™ Specialty Multiwall Carbon Nanotubes August 13th, 2014

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE